Lung Cancer in People Who Never Smoked: Why It’s Rising in India

One of the most important shifts in cancer medicine over the last decade is this: a large and growing share of lung cancer patients in India have never smoked. Lung cancer is no longer only a smoker’s disease — and understanding why matters, because it changes how these cancers should be tested and treated.

Several factors contribute, and research is ongoing:

• Air pollution — long-term exposure to fine particulate matter, a major issue in many Indian cities
• Second-hand smoke and indoor biomass-fuel smoke
• Genetic and molecular factors — non-smokers’ lung cancers are often driven by specific gene changes

Importantly, lung cancer in non-smokers — more common in women and in younger patients than many expect — tends to be biologically different from smoking-related lung cancer, and that difference is good news for treatment.

Lung cancers in non-smokers are far more likely to carry a specific, targetable driver mutation — such as EGFR, ALK or ROS1. When one of these is found, treatment can often be a targeted therapy taken as a tablet, which is frequently more effective and better tolerated than chemotherapy for that patient.

This is why comprehensive molecular testing is essential in lung cancer today — and why it should be done before treatment is finalised. It is the heart of precision medicine: matching the drug to the tumour’s biology rather than treating every lung cancer the same way.

Lung tumours can be difficult or unsafe to biopsy repeatedly. A liquid biopsy — a blood test that detects tumour DNA — can sometimes identify key mutations without more tissue, and is especially useful for detecting resistance mutations if a targeted therapy stops working, so treatment can be switched.

Care is coordinated by a lung cancer specialist, and if a plan has been made without molecular testing, a second opinion to confirm testing is complete is well worth it.

Can non-smokers really get lung cancer?
Yes, and increasingly so. Air pollution, second-hand and indoor smoke, and specific genetic factors all contribute.

Is non-smoker lung cancer treated differently?
Often, yes — because it more frequently carries a targetable mutation that can be treated with targeted tablets rather than chemotherapy.

What test should I make sure is done?
Comprehensive molecular/biomarker testing (EGFR, ALK, ROS1, PD-L1 and others) on the biopsy, or via liquid biopsy where tissue is limited.

Does this mean I won’t need chemotherapy?
Not necessarily — it depends on the result. But testing ensures you receive the most effective treatment for your specific tumour.

Related reading: Lung Cancer Specialist · Targeted Therapy · Molecular Oncology · Precision Medicine · Liquid Biopsy · Second Opinion for Cancer · Cancer Second Opinion

Further reading:

Reviewed by Dr. Harish Kancharla
DM (Medical Oncology), AIIMS, New Delhi · MD (Internal Medicine), PGIMER, Chandigarh
Senior Consultant – Medical Oncology & Hemato-Oncology, Yashoda Hospitals, Somajiguda, Hyderabad
Telangana State Medical Council Registration No. 77186
Last reviewed: August 2026

This article is general information, not personal medical advice. Cancer decisions depend on your individual diagnosis, stage, test results and overall health. Please see our Medical Disclaimer.